Organized proteomic heterogeneity in colorectal cancer liver metastases and implications for therapies

Andrei Turtoi1, Arnaud Blomme, Delphine Debois

  • 1Metastasis Research Laboratory, GIGA Cancer, University of Liège, Liège, Belgium; Mass Spectrometry Laboratory, GIGA Research, University of Liège, Liège, Belgium.

Abstract

Insights

Tumor heterogeneity in colorectal cancer liver metastases shows an organized protein pattern. This discovery enables developing targeted therapies using multiple biomarkers for improved treatment strategies.

Area of Science:

  • Proteomics
  • Cancer Biology
  • Metastasis Research

Background:

  • Tumor heterogeneity poses a significant challenge to effective cancer treatment.
  • Genetic heterogeneity in tumors often lacks discernible patterns for targeted therapy.
  • Limited information exists on protein-level heterogeneity in tumors.

Purpose of the Study:

  • To explore the heterogeneity of extracellular and membrane subproteomes in human colorectal carcinoma (CRC) liver metastases.
  • To identify spatial patterns of protein expression and their functional implications.
  • To assess the potential for developing novel therapeutic targets based on proteomic patterns.

Main Methods:

  • Matrix assisted laser desorption ionization (MALDI) image-guided proteomics.
  • Analysis of extracellular and membrane subproteomes in eight human CRC liver metastases.
  • Spatial distribution monitoring of over 1,000 proteins.

Main Results:

  • Discovered a reproducible, zonally delineated pattern of functional and therapeutic biomarker heterogeneity across all liver metastases.
  • Identified distinct metabolic and activity profiles in the peritumoral, rim, and center regions of metastases.
  • Revealed zonal expression of known and novel biomarkers, including LTBP2 and TGFBI, suitable for therapeutic targeting.

Conclusions:

  • Proteome heterogeneity in human CRC liver metastases exhibits an organized, zonal pattern.
  • This organized pattern can guide the development of rational therapies targeting multiple antigens.
  • Novel antigens LTBP2 and TGFBI show potential for clinical application in CRC liver metastasis treatment.

Related Concept Videos